Actuate elraglusib Phase 2 meets primary endpoint with statistically significant OS improvement in mPDAC

ACTUATE THERAPEUTICS, INC.

Elraglusib plus GnP showed statistically significant overall survival improvement vs GnP alone in first-line mPDAC.
Median overall survival substantially improved from December 2024 analysis; 1-year survival rate also significantly increased.
Trial achieved primary endpoint; favorable risk-benefit profile; data to be presented at ASCO on May 31, 2025.
Company plans to meet with US and EU regulators in H2 2025 to advance toward NDA and registration.
This is the first major advance in first-line mPDAC survival in over a decade, per management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.